Skip to main content
SNYR
NASDAQ Life Sciences

Synergy CHC Corp. defaults on $17.6M term loan as forbearance ends

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Negative
Importance info
9
Price
$0.165
Mkt Cap
$2.481M
52W Low
$0.161
52W High
$3.99
52W Position info
2.4% above low
Off High info
96% below high
Rel. Volume
Market data snapshot near publication time

SNYR is trading near its 52-week low of $0.161 (2.4% above the low).

Summary

Synergy CHC Corp. received a default notice after failing to make an interest payment on its $17.6 million term loan. The forbearance period has ended, and the lender can now accelerate the debt.


Key Events · Legal and Risk Events · SNYR

  • Default on $17.6M Term Loan

    ACP Agency, LLC issued a default notice after Synergy CHC Corp. failed to make the interest payment due August 3, 2026, with the cure period expiring August 6.

  • Forbearance Terminated

    The forbearance agreement dated May 28, 2026, was terminated as a result of the default, and a forbearance fee of $404,173.06 is now due and payable.

  • Lender Rights Accelerated

    ACP reserved all rights under the Credit Agreement, including charging post-default interest, accelerating the $17.6 million principal, and exercising other remedies.

  • Precarious Financial Position

    The default follows the recent loss of Costco as a customer (representing a significant portion of revenue) and a Nasdaq delisting notice, with the stock trading near its 52-week low of $0.1611.


Analysis · SNYR · Life Sciences

A missed interest payment on its $17.6 million term loan has triggered a default notice from agent ACP, putting Synergy CHC Corp. in a precarious position. The forbearance agreement that had been keeping lenders at bay is now terminated, and a $404,173 forbearance fee is immediately due. With the stock trading near all-time lows and the company already reeling from the loss of its largest customer, this default puts the entire capital structure at risk — acceleration of the full $17.6 million could force a restructuring or bankruptcy.

At the time of this filing, SNYR was trading at $0.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5M. The 52-week trading range was $0.16 to $3.99. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SNYR - Latest Insights

SNYR
Jul 29, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
10
Price at Filing: $0.1597
Real-time Price: $0.164 info
Change: +$0.0043 (+3%) info
Market Cap: $2.481M info
SNYR
Jun 29, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.2073
Real-time Price: $0.164 info
Change: -$0.0433 (-21%) info
Market Cap: $2.481M info
SNYR
May 18, 2026, 9:01 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.2861
Real-time Price: $0.164 info
Change: -$0.1221 (-43%) info
Market Cap: $2.481M info
SNYR
May 15, 2026, 5:07 PM EDT
Filing Type: S-1
Importance Score:
9
Price at Filing: $0.2821
Real-time Price: $0.164 info
Change: -$0.1181 (-42%) info
Market Cap: $2.481M info
SNYR
May 14, 2026, 8:19 AM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.305
Real-time Price: $0.164 info
Change: -$0.141 (-46%) info
Market Cap: $2.481M info